Display Settings:

Format

Send to:

Choose Destination
    Am J Pathol. 1998 Sep;153(3):845-55.

    Complement-mediated killing of microtumors in vitro.

    Source

    Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Finland.

    Abstract

    Complement-mediated lysis of cancer cells growing in three-dimensional aggregates involves factors that are not associated with the killing of cells in suspension. We have used multicellular tumor spheroids established from breast carcinoma (T47D) and ovarian teratocarcinoma (PA-1) cell lines as models to study complement-mediated destruction of micrometastases and small solid tumors. We found that significant killing of microtumors treated with an antitumor antibody and a specific monoclonal antibody (YTH53.1) against the complement lysis inhibitor protectin (CD59) started to occur after a 1 to 2-hour lag phase. After an overnight incubation, the microtumors became totally infiltrated by the YTH53.1 monoclonal antibody and C1q, whereas C3 and C5b-9 penetrated as a frontier to the peripheral cell layers. A 51Cr release assay showed that during a 24-hour pulsed treatment with complement, 33% of cells in the spheroids were killed, and the average tumor volume decreased by 28%. According to propidium iodide staining, complement exposure resulted in killing and peeling off of the outermost tumor cells.

    PMID:
    9736033
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC1853009
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 2.
    Figure 4.
    Figure 1.
    Figure 3.
    Figure 5.

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk